Emzor Pharmaceuticals has unveiled plans to establish an Active Pharmaceutical Ingredients (API) facility in Shagamu, Ogun State, with a substantial investment totaling $23 million in an effort to combat the pervasive threat of malaria in Nigeria and Sub-Saharan Africa.
In a joint statement released by Kunle Faloye, Head of Marketing and Strategy, and Uzoma Ezeoke, Executive Director, Emzor pharmaceuticals reaffirmed its commitment to addressing the urgent public health challenge posed by malaria.
Emzor emphasized its dedication to malaria eradication through rigorous research and development initiatives.
The establishment of the API plant marks a significant milestone in enabling local production of essential pharmaceutical ingredients crucial for manufacturing antimalarial drugs.
Upon completion, the API facility is expected to produce 400 metric tonnes of quality APIs annually, significantly accelerating the fight against malaria in Africa.
Emzor Pharmaceuticals secured €14 million from the European Investment Bank to establish the first active pharmaceutical ingredient (API) manufacturing plant to accelerate malaria treatments.